Antifungal effects of statins

Area of Science:

• Mycology
• Pharmacology
• Infectious Diseases

Background:

• Fungal infections cause millions of deaths annually, with rising antimicrobial resistance necessitating new therapeutic strategies.
• Statins, primarily used for cholesterol reduction, are being investigated for additional therapeutic properties.
• Potential pleiotropic effects of statins include anti-inflammatory and antimicrobial activities.

Purpose of the Study:

• To review existing in-vitro, in-vivo, and clinical data on the antifungal efficacy of statins.
• To explore modulators and mechanisms of statin's antifungal activity.
• To assess the potential of statins as antifungal agents or adjuncts.

Main Methods:

• Systematic review of in-vitro and in-vivo studies.
• Analysis of clinical reports and observational cohort studies.
• Evaluation of mechanistic studies on statin-fungal interactions.

Main Results:

• Statins exhibit broad-spectrum antifungal activity against diverse fungi, including Candida spp., Aspergillus spp., and Saccharomyces cerevisiae.
• Synthetic statins, particularly fluvastatin, show potent fungicidal/fungistatic properties at clinically achievable concentrations.
• Statins synergistically enhance the efficacy of established antifungal drugs like azoles and polyenes.

Conclusions:

• Statins possess notable antifungal properties and can potentiate existing antifungal therapies.
• Fluvastatin emerges as a highly effective statin with broad antifungal action.
• Further clinical research is essential to validate the role of statins in managing fungal infections and reducing associated complications.